More detailed requirements for pharmaceutical companies’ relationships with patient groups and health professionals will be included in the revised ABPI Code of Practice which comes into effect on July 1
Many of the changes relate to even greater transparency, and include:
As well as changes based on the two codes of the European Federation of Pharmaceutical Industries and Associations (EFPIA), others include heightening awareness of the need for health professionals to report adverse drug reactions (ADRs).
“The ABPI Code of Practice is continually evolving to ensure that the pharmaceutical industry and its stakeholders can have maximum confidence in the standards set for ethical and responsible behaviour of companies and staff,” said Chris Brinsmead, President of the ABPI.
“In this, the 50th year of the ABPI Code of Practice, the ABPI has not only agreed to revisions to implement the new requirements of the EFPIA code – as we are obliged to do – but also made further amendments to reflect experience, comments and suggestions received since the introduction of the 2006 code.”
Other changes include:
The changes have been approved by the ABPI following consultation, and will come into effect on July 1 with a transition period. Comments, proposals and suggestions on the code are always welcomed and, where relevant, will be considered for possible inclusion.
A summary of the changes can be viewed online.
About the ABPI:
The Association of the British Pharmaceutical Industry (ABPI) has 150 members including the large majority of the research-based pharmaceutical companies operating in the UK, both large and small. Our member companies research, develop, manufacture and supply more than 80 per cent of the medicines prescribed through the National Health Service (NHS). For further information visit: www.abpi.org.uk
Media contact: ABPI Press office, 020 7747 1410.